Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regeneron Pharmaceuticals
Biotech
Ipsen fails to land pivotal rare disease trial
Ipsen’s miss follows Regeneron's phase 3 win in the same ultrarare indication. Regeneron said it planned for a FDA submission by the end of 2025.
Gabrielle Masson
Dec 19, 2025 3:37pm
Regeneron inks $150M pact with gene writer Tessera
Dec 1, 2025 11:12am
Regeneron pledges $1B+ for ModeX multispecific antibodies
Oct 29, 2025 11:04am
Zag Bio emerges with $80M funding for Tregs diabetes candidate
Oct 28, 2025 7:00am
Regeneron does 180 on 2seventy lymphoma CAR-T
Oct 23, 2025 10:57am
Regeneron, Sanofi receive 1- to 2-month priority review vouchers
Oct 17, 2025 8:30am
